Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb

Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17, thus improving joint pain and swelling from arthritis and rash from psoriasis. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.